Antidepressant Medication Use, Weight Gain and Risk of Type 2 Diabetes Mellitus: A Population-based Study
- Mika Kivimäki, PhD (m.kivimaki{at}ucl.ac.uk)1,2,
- Mark Hamer, PhD1,
- G. David Batty, PhD1,3,
- John R. Geddes, MD, FRCPsych4,
- Adam G. Tabak, MD, PhD1,5,
- Jaana Pentti, MSc6,
- Marianna Virtanen, PhD6 and
- Jussi Vahtera, MD, PhD6,7
- From 1 Department of Epidemiology and Public Health, University College London, UK
- 2 Department of Behavioral Sciences, University of Helsinki, Finland
- 3 MRC Social & Public Health Sciences Unit, University of Glasgow, UK
- 4 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
- 5 1st Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary
- 6 Finnish Institute of Occupational Health, Helsinki, Finland
- 7 University of Turku, Turku University Hospital, Turku, Finland
Abstract
Objective— To examine antidepressant medication use as a risk factor for type 2 diabetes and weight gain.
Research design and methods— A series of nested studies within a prospective cohort of 151,347 working-aged men and women including 9197 participants with continuing antidepressant medication, 224 with severe depression, and 851 with incident type 2 diabetes mellitus during a mean follow-up of 4.8 years, as indicated by national health and prescription registers (the Public Sector study, Finland 1995-2005).
Results— In the first analysis, the cases were individuals with incident type 2 diabetes compared with matched diabetes-free controls. Antidepressant use of ≥200 defined daily doses was associated with a doubling of diabetes risk in both participants with no indication of severe depression (odds ratio 1.93, 95% CI 1.48-2.51) and participants with severe depression (odds ratio 2.65 95% CI 1.31-5.39). In the further analyses, exposed group was antidepressant users and reference group non-users matched for depression-related characteristics. The 5-year absolute risk of diabetes was 1.1% for non-users, 1.7% for individuals treated with 200-399 defined daily doses a year, and 2.3% for those with ≥400 defined daily doses (ptrend<0.0001). An average self-reported weight gain, based on repeated surveys, was 1.4 kg (2.5%) among non-users and 2.5 kg (4.3%) among users of ≥200 defined daily doses (ptrend<0.0001). Separate analyses for tricyclic antidepressants and selective-serotonin-re-uptake inhibitors replicated these findings.
Conclusions— In these data, continuing use of antidepressant medication was associated with an increased relative risk of type 2 diabetes, although the elevation in absolute risk was modest.
Footnotes
- Received June 21, 2010.
- Accepted August 27, 2010.
- Copyright © American Diabetes Association











